Suven Life Sciences Ltd (Suven)
on November 27, 2007
has announced that the European Patent Office (EPO)
granted Two Patents, 1523486 and 1581538 to Suven and
are valid until June 2022. The granted claims of the
patent include the class of selective 5-HT compounds
discovered by Suven and are being developed as
therapeutic agents and are useful in the treatment of
cognitive impairment associated with neurodegenerative
disorders like Alzheimer's, Attention deficient
hyperactivity, Huntington's disease, Parkinson &
Schizophrenia
Suven has three (3) European Patents granted until now
and all of them have been validated in all the 37
member countries of Europe including major markets
like Germany, Switzerland, Denmark, Spain, France,
United Kingdom, Italy, Netherlands, Poland, Sweden and
Finland. There are several patent applications from
Suven Discovery Research are in the pipeline that have
completed the administrative and technical diligence
from the patent offices from major countries and would
be granted shortly.
Suven has already filed its first Investigational New
Drug (IND) application with DCGI to conduct the
clinical Phase-I study on their developmental
candidate SUVN—502 and several candidates are in
discovery pipeline undergoing GLP pre-clinical
studies.
We continue to work on G-Protein coupled receptor
(GPCR) targets to discover and develop molecules
focusing on CNS disorders with unmet medical need and
high market potential, says Venkat Jasti, CEO of
Suven.
|
